Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Denosumab Market Evolve in Terms of Growth and Size by 2029?

The market size for denosumab has experienced swift expansion in the past few years. The market is set to expand from $3.27 billion in 2024 to $3.67 billion in 2025, translating to a compound annual growth rate (CAGR) of 12.1%. Progress made in clinical trials and research, FDA endorsements and regulatory breakthroughs, increased consciousness about bone health, as well as strategic collaborations and marketing drives, have been the driving forces behind the growth during this historical period.

Rapid expansion is anticipated in the denosumab market size over the coming years. It is projected to swell to “$5.48 billion in 2029 with a compound annual growth rate (CAGR) of 10.6%. The forecast period’s growth is linked to the escalating occurrence of bone metastases, enhancements in cancer therapies, pervasive osteoporosis, elevated osteoporosis awareness, and regulatory approvals for new indications. The forecast period will also witness leading trends such as strategic alliances and partnerships, integration with digital health technologies, supplemental indications and clinical applications, and progression in biosimilar development.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

What factors are expected to fuel Denosumab market growth in the coming years?

The escalating incidence of osteoporosis is anticipated to fuel the expansion of the denosumab market in the future. Osteoporosis is a health issue characterized by the weakening of bones, causing decreased bone density and an increased vulnerability to fractures. Denosumab is a treatment for osteoporosis that halts bone resorption by targeting the RANK ligand. For instance, data from the Canadian Longitudinal Study on Aging presented by the National Center for Biotechnology Information, a US-government agency, in September 2023, showed a 12.7% prevalence of osteoporosis diagnosed by physicians and a 5.9% DXA-confirmed prevalence in women living in communities among older adults. Moreover, a cross-sectional study carried out by Buttros and colleagues revealed a 24.6% prevalence of osteoporosis in postmenopausal women aged between 40 and 75, established through bone mineral density measurements. Hence, the rising incidence of osteoporosis is catalyzing the growth of the denosumab market.

The denosumab market covered in this report is segmented –

1) By Drug Classification: Prolia, Xgeva, Others

2) By Type: 60 mg, 120 mg

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

Which Trends Are Redefining The Future Landscape Of The Denosumab Industry?

Leading establishments in the denosumab market are turning their attention towards the development of novel solutions, such as primary treatments for osteoporosis, to strengthen their position in the market. Primary treatment for osteoporosis signifies the first or primary treatment option advised by medical experts for managing patients with osteoporosis. To exemplify, Boan Biotech, a biotechnology firm based in China, was given the green light in November 2022 by China’s National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, vaulting it into the position of being the first Chinese company to create a denosumab injection. The drug is also being prepared for sale in markets outside China, Europe and the United States included, with global marketing plans in place. Various treatment guidelines have recommended the drug as a primary treatment option for osteoporosis. This medication could potentially significantly reduce the likelihood of hip, non-vertebral and vertebral fractures in these patients. Furthermore, Boyoubei has the unique distinction of being the world’s first biosimilar to Prolia (the originator of denosumab) that has received marketing approval.

What Are The Most Active Companies In The Denosumab Market Today?

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Which Regional Markets Are Attracting The Most Investment In Denosumab?

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model